FDA Requests Removal of Opana ER for Risks Related to Abuse

FDA Requests Removal of Opana ER for Risks Related to Abuse | HIV.gov

FDA Requests Removal of Opana ER for Risks Related to Abuse

June 29, 2017 - Cross-Posted from FDA Newsroom

TOPICS: FDA, Hepatitis C, IDU, Opioid

[On June 8th, 2017], the U.S. Food and Drug Administration requested that Endo Pharmaceuticals remove its opioid pain medication, reformulated Opana ER (oxymorphone hydrochloride), from the market. After careful consideration, the agency is seeking removal based on its concern that the benefits of the drug may no longer outweigh its risks....[READ MORE]

Tweet this blog!